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Cognitive composite score association
with Alzheimer’s disease plaque and
tangle pathology
Michael Malek-Ahmadi1, Kewei Chen1, Sylvia E. Perez2, Anna He1 and Elliott J. Mufson2*
Abstract
Background: Cognitive composite scores are used as the primary outcome measures for Alzheimer’s disease (AD)
prevention trials; however, the extent to which these composite measures correlate with AD pathology has not
been fully investigated. Since many on-going AD prevention studies are testing therapies that target either amyloid
or tau, we sought to establish an association between a cognitive composite score and the underlying pathology
of AD.
Methods: Data from 192 older deceased and autopsied persons from the Rush Religious Order Study were used in
this study. All participants were classified at their initial evaluations with a clinical diagnosis of no cognitive impairment
(NCI). Of these individuals, 105 remained NCI at the time of their death while the remaining 87 progressed to mild
cognitive impairment (MCI) or AD. A cognitive composite score composed of eight cognitive tests was used as the
outcome measure. Individuals were classified into groups based on Consortium to Establish a Registry for Alzheimer’s
Disease (CERAD) neuropathological diagnosis and Braak stage.
Results: The rate of annualized composite score decline was significantly greater for the high CERAD (p < 0.001, d= 0.56)
and Braak (p < 0.001, d = 0.55) groups compared with the low CERAD and Braak groups, respectively. Mixed-model
repeated measure (MMRM) analyses revealed a significantly greater difference in composite score change from baseline
for the high CERAD group relative to the low CERAD group after 5 years (Δ = −2.74, 95% confidence interval (CI) −5.01
to −0.47; p = 0.02). A similar analysis between low and high Braak stage groups found no significant difference in change
from baseline (Δ = −0.69, 95% CI −3.03 to 1.66; p = 0.56).
Conclusions: These data provide evidence that decreased cognitive composite scores were significantly associated with
increased AD pathology and provide support for the use of cognitive composite scores in AD prevention trials.
Keywords: Amyloid, Tau, Cognition, Prevention, Pre-clinical, Neuropathology
Background
The recent initiation of secondary prevention trials for
Alzheimer’s disease (AD) [1, 2] has resulted in a paradigm
shift in the AD clinical research field, with the focus on
identifying individuals who are at risk of developing AD
by virtue of age, genetic risk factors, and/or the presence
of AD pathology through neuroimaging technologies.
Until more robust associations between clinical outcomes
and neuroimaging/fluid-based biomarkers are established
[3], the gold standard measure of efficacy in AD clinical
prevention trials will continue to be the clinical evaluation
of cognitive changes over time. However, the cognitive as-
sessments in AD clinical trials are not sensitive enough to
detect changes in less cognitively impaired individuals [4,
5], and therefore their use in prevention trials remains du-
bious. To identify the earliest clinically meaningful
changes in cognition, the use of a composite score com-
prised of several different cognitive tests has been pro-
posed [6]. Given that the incidence of mild cognitive
impairment (MCI) can vary greatly [7, 8], AD prevention
trials that use time-to-event as an outcome require ex-
tended observation periods to accurately assess disease
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progression. As a result, it is important that prevention
trials use measures of cognition that can demonstrate
meaningful treatment effects in the preclinical stages of
dementia with reasonable trial durations.
It has been suggested that preclinical AD can be char-
acterized by subtle cognitive changes that are detectable
via sensitive neuropsychological tests and reflect the ini-
tial stages of the disease process [9, 10]. In addition, pre-
clinical AD is also characterized by a lack of functional
decline [11], which puts greater significance on the abil-
ity to demonstrate treatment efficacy through cognitive
assessments in AD prevention trials. Therefore, em-
phasis has been directed towards the creation and valid-
ation of cognitive composite scores as primary efficacy
measures in AD prevention trials to detect subtle cogni-
tive changes between treatment and placebo groups.
Several different cognitive composite measures have
been developed [12–16] which are sensitive to subtle
cognitive decline during the preclinical phase of AD.
These composite scores were developed in different pop-
ulations using differing variables (e.g., APOE ɛ4 status,
amyloid positivity, postmortem AD neuropathology) to
differentiate preclinical AD from age-similar controls.
Others have proposed the Catch-Cog, a composite score
that combines information from performance-based cog-
nitive assessments with informant-based functional as-
sessments [17]. Furthermore, the European Prevention
of Alzheimer’s Dementia (EPAD) group has imple-
mented a comprehensive battery of cognitive tests that
assess several cognitive domains [18]. Many of the tests
in the EPAD battery are widely used verbal or paper and
pencil tests, while others are novel computer-based tasks
that are intended to measure cognitive changes associ-
ated with specific cortical regions known to be differen-
tially affected by AD pathology [18]. Although there is
evidence demonstrating that these composite scores
have good sensitivity to clinical change [12–16], it is un-
clear whether these particular composite scores correlate
with autopsy-confirmed AD pathology.
Other groups have shown that cognitive composite
scores correlate well with AD pathology among individ-
uals with no cognitive impairment (NCI) who had not
progressed to MCI or AD at the time of death [19–21].
Boyle et al. [19] showed that higher levels of both amyl-
oid and tau load were associated with longitudinal de-
creases in global cognition after adjusting for age, sex,
and education. Riley et al. [20] revealed that NCI indi-
viduals with a NIA-Reagan diagnosis of intermediate or
high likelihood of AD had significantly greater antemor-
tem cognitive decline relative to those with the no or
low likelihood diagnoses. Monsell et al. [21] reported
that NCI individuals with high levels of AD pathology
had significantly greater decline on a composite score of
attention/working memory when compared with NCI
individuals with no evidence of AD pathology. Together,
these studies provide evidence that elderly people that
died with an antemortem clinical diagnosis of NCI but
who displayed extensive AD pathology on brain neuro-
pathological evaluation postmortem show a significant
decline on a composite memory score.
Although it appears that cognitive composite score
changes correlate with the presence of AD-related path-
ology among aged individuals who are cognitively stable,
whether similar associations exist in individuals that pro-
gress to MCI or AD remains to be investigated. Since
AD prevention trials are likely to enroll individuals who
progress to MCI during the course of the study, under-
standing the nature of cognitive trajectories among pro-
gressors and nonprogressors is needed. Therefore, the
aim of this study was to define the relationship between
longitudinal changes on a cognitive composite score and
postmortem plaque and neurofibrillary tangle (NFT)
pathology among NCI individuals who did and did not
progress to MCI and AD.
Methods
The data examined were derived from 192 older de-
ceased and autopsied persons who were classified as
NCI at their initial clinical evaluation. At the last testing
within 12 months prior to death, 105 of these individuals
remained NCI while the remaining 87 progressed to
MCI (n = 40) or AD (n = 47) (Table 1). Among those
who progressed to MCI, 13 were classified as amnestic
and 27 were classified as nonamnestic. Previous work by
our group has shown that plaque and tangle pathology
does not differ significantly between amnestic and non-
amnestic MCI subjects in this cohort [22]. These indi-
viduals were participants in the Rush Religious Order
Study (RROS) [23, 24], had no coexisting clinical or
neurological conditions judged to contribute to cognitive
impairment at their last clinical evaluation [23, 24],
agreed to annual clinical evaluations, and signed an in-
formed consent and an Anatomic Gift Act donating
their brains at the time of death. Data from these sub-
jects have been used in numerous clinical pathological
studies supported by our ongoing NIA program project
grant entitled the “Neurobiology of Mild Cognitive Im-
pairment in the Elderly” (PO1AG14449). At the time of
these studies, individuals were chosen from all available
RROS participants that came to autopsy during a rolling
admission [23]. In addition, those taking anticholinester-
ases or medication for depression were also excluded.
The Human Investigation Committee of Rush University
Medical Center approved this study.
Clinical evaluation
Each of the participants underwent a uniform, struc-
tured, and clinical evaluation performed by a neurologist
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and a trained neuropsychological test technician [23,
25]. Medications used by the subjects within the previ-
ous 14 days of the examination were reviewed and clas-
sified. A neurologist reviewed the medical history,
medication use, neurologic examination, results of cog-
nitive performance testing, and the neuropsychologist’s
opinion of cognitive impairment and dementia. Each
participant was evaluated in their home, emphasizing
findings deemed clinically relevant. Clinical diagnostic
classification was performed as described previously
[23, 25]. At the time of death, individuals with a clin-
ical diagnosis of MCI or AD were classified as pro-
gressors and those classified as NCI were categorized
as nonprogressors. Progression to MCI or AD was
determined by performance on neuropsychological
tests as well as a clinical examination by a neurolo-
gist. Based on these cognitive and clinical data, a
diagnostic algorithm was used to determine the clin-
ical status of each participant [26].
Tissue preparation and neuropathological diagnosis
Brain accruement and processing was as described previ-
ously [25, 27]. Briefly, each brain was cut into 1-cm thick
coronal slabs using a brain slice apparatus and hemisected.
One hemisphere was immersion fixed in 4% paraformal-
dehyde (24–72 h) and cryoprotected (10% glycerol and 2%
dimethyl sulfoxide in phosphate-buffered solution) until
processing for immunohistochemistry.
Diagnostic blocks (mid-frontal, superior temporal, ento-
rhinal cortex, hippocampus, inferior parietal cortex, basal
ganglia, thalamus, and substantia nigra) from the opposite
hemisphere were paraffin embedded and cut at 6 μm.
Examination for cerebral infarctions was conducted as
described previously [28]. Bielschowsky silver stain was
used to visualize neuritic plaques (NPs), diffuse plaques
(DPs), and NFTs. Sections were also immunostained for
amyloid beta (Aβ) using antibody M0872 (1:100; Dako,
CA) raised against Aβ1–40 and Aβ1–42. Paired helical fila-
ment tau (AT8; 1:800, Covance) immunohistochemistry
was also used to label NFTs. Neuropathological diagnoses
were determined according to Consortium to Establish a
Registry for Alzheimer’s Disease (CERAD) [29] and Braak
staging [30] as recommended by the NIA-Reagan criteria
[31]. Exclusion criteria included mixed dementias, Parkin-
son’s disease, frontotemporal dementia, argyrophilic grain
disease, vascular dementia, hippocampal sclerosis,
stroke, and Lewy body disease. Lewy bodies in the
substantia nigra, entorhinal, cingulate, midfrontal,
middle temporal, and inferior parietal cortex were de-
tected using α-synuclein immunohistochemistry as pre-
viously described [32] and scored semiquantitatively
according to the severity and anatomical distribution,
separating brainstem predominant, limbic/transitional,
and diffuse neocortical types, depending on the ana-
tomical distribution of the α-synuclein positivity [33,
34]. A board-certified neuropathologist or trained tech-
nician, blinded to clinical diagnosis, counted the num-
ber of NPs and DPs revealed by Bielschowsky silver
stain and Tau immunohistochemistry using the phos-
phorylated paired helical filament tau AT8 marker for
NFTs, respectively, in one square millimeter area (100×
magnification) per cortical region as reported previ-
ously [35, 36]. NP and NFT counts used in this study
were a summation of counts from the entorhinal cor-
tex, CA1 hippocampus, midfrontal cortex, midtemporal
cortex, and inferior parietal cortex.
Table 1 Demographic, cognitive, and postmortem data by progression status
Progressors Nonprogressors p value Effect size
n 87 105 NA NA
Gender (male/female), n 27/60 54/51 < 0.001 NA
APOE e4 (carrier/noncarrier), n 25/62 18/87 0.06 NA
Age at baseline (years) 78.95 ± 5.93 76.40 ± 6.16 < 0.001 0.42
Age at death (years) 87.84 ± 5.67 84.48 ± 5.61 < 0.001 0.60
Education (years) 18.31 ± 3.22 18.20 ± 3.57 0.82 0.03
MMSE at baseline 28.28 ± 1.78 28.68 ± 1.39 0.08 0.25
MMSE proximate to autopsy 21.92 ± 6.61 28.30 ± 1.29 < 0.001 1.34
Length of follow-up (years) 7.65 ± 3.72 7.23 ± 4.75 0.50 0.10
Baseline composite score 67.24 ± 6.85 69.08 ± 7.37 0.08 0.26
Interval between last
clinic visit and autopsy (months)
0.69 ± 0.55 0.68 ± 0.57 0.95 0.02
Postmortem interval (h) 6.95 ± 5.15 7.11 ± 6.95 0.85 0.03
Brain weight at autopsy (g) 1165.97 ± 131.11 1224.61 ± 142.93 < 0.001 0.43
Values are shown as mean ± standard deviation unless otherwise indicated
Effect size = Cohen’s d
MMSE Mini Mental State Examination, NA not applicable
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Cognitive composite score
The composite score was comprised of eight cognitive
tests that included the CERAD Word List Delayed Re-
call, WMS-R Logical Memory (delayed recall), Category
Fluency (Fruits and Animals), Symbol Digit Modalities
Test, Ravens Progressive Matrices (9-item), Judgment of
Line Orientation (15-item), MMSE Orientation to Time,
and MMSE Orientation to Place. The composite score
used in this study is based on that of Langbaum et al.
[12], but was refined to reflect the selection of tests be-
ing used in on-going AD prevention trials [37, 38]. The
tests that comprise this composite score are the same, or
are analogous to, those used in other composite scores
[12–14]. A list of the individual tests used to create the
current composite score and others is shown in Table 2.
The tests that form the composite score are intended
to assess change in the cognitive domains of episodic
memory (CERAD Word List Delayed Recall, WMS-R
Logical Memory), attention/processing speed (Symbol
Digit Modalities Test), executive function (Ravens
Progressive Matrices), language (Category Fluency),
visuospatial function (Judgment of Line Orientation),
and orientation (MMSE Orientation to Time, and
MMSE Orientation to Place). Several of these tests
have been used in the formation of other composite
scores [13, 14, 17]. Another score utilizes the Repeat-
able Battery for the Assessment of Neuropsychological
Stats (RBANS), which includes List Learning and
Story Memory tests to assess episodic memory as well
as other tests that assess attention (Coding and Digit
Span), language (Picture Naming and Semantic Flu-
ency), and visuospatial function (Figure Copy and
Line Orientation) [18].
Individual raw scores for each test were standard-
ized to a 0 to 1 scale by subtracting the minimum
possible score for a test from the raw score and then
dividing by the difference of the maximum and mini-
mum possible scores:
Standardized score ¼ raw scoreminimum possible scoreð Þ=
maximum possible scoreminimum possible scoreð Þ
Since the Category Fluency test does not have an
established maximum score, two standard deviations
above the mean was used as the maximum. This method
has been applied previously for a similar cognitive com-
posite score [12]. No adjustments for directionality were
needed since lower scores are indicative of decreased
performance for all tests. The standardized scores for
each test were then summed and divided by eight (the
number of tests) to obtain an unweighted average. Fi-
nally, for scaling purposes, standardized scores were
multiplied by 100.
An annualized rate of change for the composite score
was calculated by subtracting the score at the last visit
from the baseline score and then dividing by the differ-
ence in age between the two visits.
Annualized change ¼ score at last visit score at baselineð Þ=
age at last visit age at baselineð Þ
Statistical analysis
Between-group frequency differences for categorical var-
iables were analyzed using the Chi-square test while
between-group differences for continuous variables were
compared with a two-sample t test. Annualized cognitive
composite score change differences for CERAD neuro-
pathological diagnosis and Braak stage were evaluated
using a one-way analysis of variance (ANOVA). Braak
stage was divided into three groups (0 to II, III, and IV
to V) to maintain adequate group sizes for the ANOVA.
This Braak stage grouping scheme also allowed for the
transentorhinal stage (I and II) of NFT deposition to be
differentiated from the intermediate limbic stage (III)
[28]. Braak stage III was grouped independently since
the transition from Braak stage III to IV is thought to
coincide with the transition from normal cognition to
Table 2 Composite score comparison between studies
Publication Composite score components
Current study CERAD Word List Delayed Recall, WMS-R Logical Memory (Delayed Recall), Category Fluency, Symbol Digit Modalities Test,
Ravens Progressive Matrices (9-Item), Judgment of Line Orientation (15-Item), MMSE Orientation to Time, MMSE Orientation
to Place.
Langbaum et al. [12] East Boston Memory Test (Immediate Recall), WMS-R Logical Memory (Delayed Recall), Boston Naming Test (15-Item),
Category Fluency, MMSE Orientation to Time, Ravens Progressive Matrices (9-Item), Symbol Digit Modalities Test
Donohue et al. [13] Free and Cued Selective Reminding Test (Total Score), MMSE (Total Score), WMS-R Logical Memory (Delayed Recall), WAIS-R
Digit Symbol Substitution
Coley et al. [14] MMSE Orientation to Time, MMSE Orientation to Place, Free and Cued Selective Reminding Test (Total Score), Category
Fluency, Trail-Making Test Part B
Jutten et al. [17] ADAS-Cog Word Recall, ADAS-Cog Word Recognition, ADAS-Cog Orientation, Digit Span Backward, Controlled Oral Word
Association Test, Category Fluency, Digit Symbol Substitution Test
Ritchie et al. [18] RBANS List Learning, RBANS Story Memory, RBANS Figure Copy, RBANS Line Orientation, RBANS Picture Naming, RBANS
Semantic Fluency, RBANS Coding, RBANS Digit Span, NIH Examiner Toolbox Dot Counting, NIH Examiner Toolbox Paired
Associate Learning, NIH Examiner Toolbox Eriksen Flanker Task, Four Mountains Task
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dementia [39]. Stages IV and V were grouped together
as none of the subjects were classified in stage VI. The
Tukey HSD test was used for post-hoc group-wise
comparisons.
Annualized composite score change was also analyzed
when the cases were grouped based on pathology sever-
ity as measured by CERAD criteria and Braak stage. The
low CERAD group consisted of those with the no AD
classification, while possible, probable, and definite AD
were classified as high CERAD. Low Braak stage con-
sisted of individuals ranging from 0 to II and high Braak
stage included individuals ranging from III to V.
In addition, mixed-model repeated measure (MMRM)
analyses were used to examine change from baseline dif-
ferences on the composite score between high and low
pathology groups. In these analyses, time was treated as
a categorical variable and data were restricted to the first
six visits for each subject (baseline plus 5 years of
follow-up). This follow-up length was selected to ap-
proximate the duration of current AD prevention trials
[2, 37, 38]. Unstructured covariance structure was
attempted for all models. In the event that the models
did not converge, autoregressive order 1 (AR(1))
followed by variance component (VC) structures were
used. Kenward-Roger approximation for degrees of free-
dom was used for all models. The MMRM models in-
cluded fixed-effects for visit, age at baseline, gender,
education, APOE ε4 carrier status, baseline composite
score, pathology group, and visit by pathology group
interaction. The primary outcome for each analysis was
the least-squares difference of composite score change
between the low and high pathology groups. Separate
MMRM models were carried out to compare change
from baseline differences in high versus low CERAD and
high versus low Braak stage. A third MMRM model was
carried out which grouped the participants based on
both their CERAD and Braak stage status (high CERAD/
high Braak, low CERAD/low Braak, and intermediate
(high CERAD/low Braak and low CERAD/high Braak)).
The t tests and ANOVA were carried out using
SYSTAT 13.1 (SYSTAT Software Inc., San Jose, CA).
SAS Enterprise Guide 6.1 (SAS Institute, Cary, NC) was
used for the MMRM analyses. Statistical significance
was set at p ≤ 0.05.
Results
Demographic and postmortem characterization
Demographic, cognitive, and postmortem characteristics
of the study sample are shown in Table 1. Females were
more likely to progress to MCI/AD than males (p <
0.001). APOE ε4 status was not associated with disease
progression (p = 0.06). Individuals who progressed to
MCI or AD were approximately 2.5 years older than
nonprogressors at baseline (p < 0.001). Progressors were
also significantly older at their time of death relative to
nonprogressors (p < 0.001); however, the two groups did
not differ on years of education (p = 0.82), baseline Mini
Mental State Examination (MMSE) (p = 0.08), length of
follow-up (p = 0.50), or baseline composite score (p =
0.08). MMSE proximate to death was significantly lower
for progressors (p < 0.001). The interval between the last
clinic visit and death and postmortem interval were not
significantly different (p = 0.95 and p = 0.85, respect-
ively). Progressors had significantly lower brain weight at
autopsy compared with nonprogressors (p < 0.001).
For the neuropathological variables (Table 3), CERAD
neuropathological diagnosis prevalence of the no AD
classification was significantly higher among nonpro-
gressors (p < 0.001). Braak stage V was more prevalent
among progressors than nonprogressors (p = 0.01).
Cognitive composite score and neuropathology
associations
Annualized composite score change between the CERAD
classifications was significantly different (p < 0.001), with
the no AD group showing a significantly slower rate of
change relative to the probable AD (p = 0.01) and definite
AD groups (p < 0.001) (Fig. 1). All other CERAD
group-wise comparisons were not significantly different.
For Braak stage, the 0 to II group showed a significantly
slower annualized composite score change relative to the
III (p = 0.01) and IV to V (p < 0.001) groups (Fig. 2). The
Braak stage III and IV to V groups were not significantly
different (p = 0.99).
Significant differences for the annualized cognitive
composite score change was noted for both the CERAD
and Braak stage groupings (both p < 0.001) with medium
effect sizes (CERAD d = 0.56; Braak stage d = 0.55). Data
for these analyses are shown in Table 4.
Table 3 Neuropathological data by progression status
Progressors (n) Nonprogressors (n) p value
CERAD neuropathological
diagnosis
< 0.001
No AD 18 41
Possible AD 6 14
Probable AD 39 38
Definite AD 24 12
Braak stage 0.01
0 0 2
I 9 19
II 7 17
III 24 31
IV 23 31
V 24 5
AD Alzheimer’s disease
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The MMRM analysis for the CERAD grouping
showed that the composite score change from base-
line difference between the high and low CERAD
groups was statistically significant (Δ = −2.74, 95%
confidence interval (CI) −5.01 to −0.47; p = 0.02), with
the high CERAD group showing a significantly greater
change from baseline (Fig. 3). For Braak stage, the
composite score change from baseline difference be-
tween the low and high groups was not statistically
significant (Δ = −0.69, 95% CI −3.03 to 1.66; p = 0.56).
Although the high/low Braak stage group difference
was not statistically significant, independently, these
groups both showed a statistically significant decline
from baseline (high Braak: Δ = −3.99, 95% CI −5.25 to
−2.74; p < 0.001; low Braak: Δ = −3.30, 95% CI −5.38
to −1.23; p = 0.002) (Fig. 4).
For the three-group analysis, the group sizes were as
follows: high CERAD/high Braak, n = 56; intermediate,
n = 53; low CERAD/low Braak, n = 83. The composite
score change from baseline difference between the high
CERAD/high Braak and the low CERAD/low Braak was
not statistically significant (Δ = −0.78, 95% CI −3.81 to
2.24; p = 0.61). Further examination of the low CERAD/
low Braak group found that eight individuals who pro-
gressed had composite score change from baseline esti-
mates ranging from −2.15 to −21.70 (mean ± SD, −7.28
± 6.61), which could explain the nonsignificant differ-
ence with the high CERAD/high Braak group. The inter-
mediate group showed a significantly greater change
from baseline than the low CERAD/low Braak group (Δ
= 3.85, 95% CI 0.55–7.15; p = 0.02). Composite score de-
cline for the high CERAD/high Braak group was signifi-
cantly greater than that of the intermediate group (Δ =
−4.63, 95% CI −7.09 to −1.58; p = 0.002) (Fig. 5).
Within-group and between-group change from baseline
estimates for each MMRM model are shown in Table 5.
AR(1) covariance structure was used for all MMRM
models due to a lack of convergence when using un-
structured covariance.
Post-hoc MMRM analyses
When change from baseline differences for APOE ε4 car-
rier status were assessed, ε4 carriers were found to have
significantly greater change from baseline relative to ε4
noncarriers (Δ = −3.15, 95% CI −5.63 to −0.66; p = 0.01).
For progression status, progressors displayed significantly
greater change from baseline than nonprogressors (Δ =
−7.51, 95% CI −9.48 to −5.53; p < 0.001). MMRM models
restricted to nonprogressors were performed to determine
the effect of pathology group differences on the composite
score. For high/low CERAD groups, the difference in
change from baseline was not statistically significant (Δ =
−1.17, 95% CI −3.39 to 1.05; p = 0.30). The difference for
the high/low Braak groups was also not significant (Δ =
0.52, 95% CI −1.78 to 2.82; p = 0.66).
Fig. 1 Annualized composite score change by CERAD neuropathological
diagnosis. Boxes represent the mean and error bars are standard
deviation. No Alzheimer’s disease (AD) vs probable AD, p = 0.01;
no AD vs definite AD, p< 0.001; all other group-wise comparisons were
not significantly different
Fig. 2 Annualized composite score change by Braak stage. Boxes
represent the mean and error bars are standard deviation. 0 to II vs
III, p = 0.01; 0 to II vs IV to V, p < 0.001; III vs IV to V, p = 0.99
Table 4 Annualized cognitive composite score change differences
for high and low pathology groupings
High Low p value Effect size
CERAD −1.59 ± 2.40 −0.26 ± 2.36 < 0.001 0.56
n = 133 n = 59
Braak stage −1.57 ± 2.23 −0.19 ± 2.75 < 0.001 0.55
n = 138 n = 54
Values are shown as mean ± standard deviation
Effect size = Cohen’s d
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Z score standardization of the composite score
An additional analysis was performed using a z score
transformation to create the composite score. The indi-
vidual cognitive tests at each visit were standardized to
the mean and standard deviation of their baseline values,
which generated a z score for each raw test value. The z
scores for each individual at each visit were summed
and divided by eight to create a composite z score.
Change from baseline analyses for the composite z score
were conducted similar to the previous MMRM ana-
lyses. The high CERAD group showed worse perform-
ance relative to the low CERAD group on the composite
z score, but this difference was not statistically signifi-
cant (Δ = −0.16, 95% CI −0.33 to 0.01; p = 0.06). The
composite z score difference for the high and low Braak
stage groups was also not significant (Δ = −0.03, 95% CI
−0.20 to 0.14; p = 0.74). For the three-group analysis, the
composite z score results were similar to the previous
three-group analysis where the high CERAD/Braak
group had significantly greater decline than the
intermediate group (Δ = −0.33, 95% CI −0.50 to −0.15;
p < 0.001), but not the low CERAD/Braak group (Δ =
0.00, 95% CI −0.23 to 0.22; p = 0.98). Similar to the pre-
vious analysis, the intermediate group had significantly
better performance than the low CERAD/Braak group
(Δ = 0.32, 95% CI 0.08–0.57; p = 0.01).
Discussion
The results of this study demonstrate a significant asso-
ciation between AD-related amyloid and tau pathology
and a cognitive composite score similar to those used in
on-going AD prevention trials [12–14, 38, 39]. In
addition, these findings serve to establish a relatively ro-
bust association between a cognitive outcome and AD
pathology. Our results also provide empirical support for
the use of cognitive composite scores as a primary out-
come for AD prevention trials. Although many of the
current AD therapies in clinical trials are focused pri-
marily on amyloid reduction [40], the continued devel-
opment of tau-directed treatments [41] will require that
cognitive composite scores correlate well with both AD
lesions. These results are important in light of the Food
and Drug Administration’s (FDA) revised guidance for
drug development in early AD [9], which indicates that
approval for a new treatment could be obtained based
on a “persuasive effect” on a cognitive outcome. How-
ever, the guidelines emphasize that a study sponsor must
demonstrate that cognitive function is related to
underlying disease pathology in a broader clinical
context (certainty of diagnosis and future clinical
course) [9]. Previous studies have shown that cogni-
tive trajectories in cognitively stable individuals are
impacted by the severity of AD pathology [19–21].
Here we found the same association in a mixed sam-
ple of progressors and nonprogressors. Since AD pre-
vention trials are likely to include individuals who
will progress to MCI during the course of the trial,
including these subjects in our analysis provides a
more accurate estimate of cognitive trajectories in the
context of an AD prevention trial.
Since other currently used composite scores [13, 14, 17,
18] are comprised of the same, or similar, cognitive sub-
tests to those employed here, it is likely that their associ-
ation with AD pathology would be comparable with our
composite score. Although the FDA’s revised guidance for
early AD drug development [9] provides greater latitude
in the use of cognitive outcomes for efficacy analyses,
there is still a need to demonstrate that observed cognitive
Fig. 3 Least squares composite score estimates for high and low CERAD groups. Group difference in change from baseline was statistically
significant (Δ = −2.74, 95% CI −5.01 to −0.47; p = 0.02). Error bars indicate standard error
Malek-Ahmadi et al. Alzheimer's Research & Therapy  (2018) 10:90 Page 7 of 12
changes are associated with underlying disease pathology
as suggested by the current study.
This present study also lends support to the require-
ment that potential subjects display positive amyloid
scans to meet inclusion criteria in AD prevention trials.
Since AD prevention trial inclusion criteria include clin-
ically asymptomatic individuals with significant AD
pathology who are at a higher risk for the development
of cognitive symptoms, it is these individuals in which
preclinical intervention(s) may significantly delay or halt
the onset of clinical decline. The results derived from
the CERAD high/low grouping show that individuals
with high plaque load had significantly greater annual-
ized declines on the composite score relative to those
with low plaque load. In addition, the medium effect size
(d = 0.56) indicates clinical relevance for this difference.
Amyloid imaging evidence has shown that decreased
performance in several different cognitive domains is as-
sociated with greater amyloid load in cortical regions as-
sociated with AD (e.g., precuneus, anterior cingulate,
posterior cingulate, temporal cortex, pre-frontal cor-
tex, etc.) [42]. Others have shown that increased
Fig. 4 Least squares composite score estimates for high and low Braak stage. Group difference in change from baseline was not statistically
significant (Δ = −0.69, 95% CI −3.03 to 1.66; p = 0.56). Within-group change from baseline was statistically significant for both groups (high Braak:
Δ = −3.99, 95% CI −5.25 to −2.74; p < 0.001; low Braak: Δ = −3.30, 95% CI −5.38 to −1.23; p = 0.002). Error bars indicate standard error
Fig. 5 Least squares composite score estimates for high, intermediate, and low pathology groups. Group differences in change from baseline
were statistically significant for intermediate vs. low (p = 0.01) and intermediate vs high (p < 0.001), but not for high vs. low (p = 0.61). Error bars
indicate standard error
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plaque and NFT pathology in the entorhinal cortex,
CA1, and subiculum is associated with worse ante-
mortem memory performance [43]. Our findings are
similar to these domain- and region-specific cognition
and pathology associations.
MMRM analysis did not reveal significant differences
in composite score trajectory between the low and high
Braak groups (p = 0.56), indicating that the groups had
similar rates of decline (Fig. 4). In addition, the MMRM
analysis of the low and high CERAD groups showed that
the high CERAD group had a significantly greater
change from baseline relative to the low CERAD group
(p < 0.001). Furthermore, an additional MMRM analysis
revealed that individuals in the high CERAD and high
Braak stage groups exhibited greater change from base-
line relative to the intermediate pathology group. The
lack of significance between the high CERAD/high Braak
and the low CERAD/low Braak groups is surprising, but
may be driven by the inclusion of eight progressors in
the low CERAD/low Braak cohort that showed signifi-
cant cognitive decline. Overall, these results suggest that
increased plaque burden drives the observed change in
the composite score, which contrasts with other studies
showing that both NFTs and NPs are associated with
cognitive decline [44, 45]. A study by our group found a
lack of association between NFT load and cognition in a
cross-sectional analysis [46], but in a subsequent longi-
tudinal analysis we found that the interaction of higher
Braak stage, older age, and positive APOE ε4 status were
associated with declines in episodic memory and execu-
tive function in NCI older adults [47]. Furthermore, we
previously found that decreased cognitive performance
in NCI subjects in a cross-sectional study was associated
with NP load and not DP load [48].
The finding that the intermediate pathology group
performed significantly better than the low CERAD/low
Braak stage group in the three-group MMRM analysis is
curious. A possible explanation might be that cognitive
reserve mechanisms allowed the intermediate group to
maintain cognitive function in the presence of plaque or
tangle pathology [46, 49]. However, of the 53 subjects in
the intermediate group, 29 displayed high Braak path-
ology raising the possibility that these may be cases of
neurofibrillary tangle predominant dementia (NFTPD)
in which the APOE ε4 allele is less prevalent and cogni-
tive impairment is less severe relative to sporadic AD
[50, 51]. Only three of the 29 high Braak subjects were
APOE ε4 carriers and this group did not show a signifi-
cant decline from baseline. The lack of cognitive com-
posite score decline in the high Braak group may also
suggest the presence of primary age-related tauopathy
(PART), which is characterized by the presence of NFT
pathology with no or minimal amyloid plaque deposits
and is associated with a lack of cognitive decline and
low APOE ε4 prevalence [52]. Since these cases dis-
played both plaque and tangle pathology, they do not
meet the criteria for PART.
Another important issue raised by this study is the
relative discordance of neuropathological and clinical
status and its impact on the interpretation of composite
score differences. Here we found that the probable AD
CERAD diagnosis and advanced Braak scores were rela-
tively equal between progressors and nonprogressors.
Heterogeneity of AD neuropathology among NCI indi-
viduals has been reported previously by our group in the
population examined here [46–48], which may be re-
lated to the observation that some of the CERAD diag-
nostic groups were not significantly different on the
annualized composite score change. When high and low
pathology status was considered, annualized change was
significantly lower among the high CERAD and high
Braak stage groups with effect sizes that also indicated
clinical relevance. Although it is unclear whether these
effect sizes relate to treatment efficacy, they suggest that
significant treatment effects could be observed if
disease-modifying therapies are initiated early.
Composite scores have been used as clinical trial end-
points in other therapeutic areas [53], allowing for mul-
tiple components of a particular outcome to be
measured in a single index. Since the clinical presenta-
tion of MCI and AD can differ in terms of which cogni-
tive domains show the earliest decline, cognitive
Table 5 MMRM-estimated cognitive composite score change from baseline results
Δ from baseline p value Δ from low group p value
Low CERAD − 1.80 (−3.79, 0.19) 0.08 NA NA
High CERAD −4.54 (−5.80, −3.28) < 0.001 −2.74 (−5.01, − 0.47) 0.02
Low Braak −3.30 (−5.38, −1.23) 0.002 NA NA
High Braak −3.99 (−5.25, −2.74) < 0.001 −0.69 (−3.03, 1.66) 0.56
Low CERAD/low Braak −4.34 (−7.09, −1.58) 0.002 NA NA
Intermediate −0.49 (−2.52, 1.54) 0.64 3.85 (0.55, 7.15) 0.02
High CERAD/high Braak −5.12 (−6.48, −3.76) < 0.001 −0.78 (−3.81, 2.24) 0.61
Values are shown as least-squares mean (95% confidence interval)
NA not applicable
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composite scores allow for these changes to be observed
while not requiring additional statistical power if each
cognitive test were treated as separate outcomes. More-
over, how components of a composite score are
weighted is also an important issue [54, 55]. Donohue
and colleagues [13] commented that differing weights
among the components of a cognitive composite score
are not easily attained since there is no a priori evidence
of how a weighting scheme relates to a treatment re-
sponse. In addition, implementing a fixed weighting
scheme assumes a degree of homogeneity in the clinical
presentation and course of decline in cognitive domains.
Since decline in nonmemory domains may not occur at
the same frequency or at the same trajectory between in-
dividuals, giving equal weight to the components of a
composite score might allow for cognitive decline to be
measured more accurately in the presence of heteroge-
neous clinical presentations. Others have shown relative
improvement in treatment-effect detection using linear
weights in a cognitive composite score [55]; however,
the use of linear weighting may produce only marginal
gains in statistical power [55].
Another challenge in the interpretation of the current
findings is the follow-up timeframe. Although we re-
stricted the follow-up length to 5 years to approximate
that of AD prevention trials, it is reasonable to expect
that many individuals may develop clinical symptoms of
MCI/AD after this timeframe. Therefore, the prognostic
value of these results may be limited. In this study, the
composite score differences were not clear until year 4,
and it is likely that these differences were driven by pro-
gressors with high pathology. An additional limitation is
the relatively small number of APOE ε4 carriers, particu-
larly homozygous individuals, which may affect the asso-
ciations reported here. Future studies with a greater
balance of APOE ε4 carriers and noncarriers will extend
these results. The subjects in this study were from a
community-based group of highly educated retired
clergy who had excellent healthcare and nutrition and
were used in multiple clinical pathological [56] and epi-
demiological investigations [35]. Individuals who volun-
teer may introduce bias by decreasing pathology, but
this is partially mitigated by high follow-up and autopsy
rates of the RROS [27]. The findings presented here may
be limited to a less heterogeneous population since the
individuals examined were virtually absent of vascular or
other comorbid neuropathology. Since vascular lesions
and other neuropathologies frequently occur in the pres-
ence of classic AD pathology, this cohort is more repre-
sentative of those individuals that would be chosen for
an AD clinical prevention trial.
Study strengths include uniform premortem clinical
and postmortem pathological evaluation and that the
final pathologic classification was performed without
knowledge of the clinical evaluation. An additional
strength is that our results are easily translatable to clin-
ical trials since the MMRM approach is often used to
analyze the primary outcome of AD clinical trials [57–
63]. In this study, the selection of covariates is similar to
that used in the efficacy analyses of clinical AD trials
[57–63]. Furthermore, the cognitive composite score
used in the present investigation is similar to composites
currently being used in on-going AD prevention trials
[12–14, 37, 38], which adds to the generalizability of our
findings.
Conclusion
The results of this study are prescient given that cogni-
tive composite scores are being utilized as primary out-
comes in AD prevention trials. The findings presented
here establish that cognitive composite score perform-
ance correlates well with AD pathology in a preclinical
context. By showing that a clinical outcome is associated
with treatment targets of on-going AD prevention trials,
these results may provide additional support for preven-
tion trials that demonstrate beneficial treatment effects.
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